CXCL13 plus interleukin 10 is highly specific for the diagnosis of CNS lymphoma
James L. Rubenstein,Valerie S. Wong,Cigall Kadoch,Hua Xin Gao,Ramon F. Barajas,Lingjing Chen,S. Andrew Josephson,Brian J. Scott,Vanja C. Douglas,Mekhala Maiti,Lawrence D. Kaplan,Patrick A. Treseler,Soonmee Cha,Jimmy Hwang,Paola Cinque,Jason G. Cyster,Clifford A. Lowell +16 more
Reads0
Chats0
TLDR
It is demonstrated for the first time that elevated CXCL13 concentration in cerebrospinal fluid (CSF) is prognostic and that CXC chemokine ligand and IL-10 mediate chemotaxis of lymphoma cells isolated from CNS lymphoma lesions.About:
This article is published in Blood.The article was published on 2013-06-06 and is currently open access. It has received 178 citations till now. The article focuses on the topics: Lymphoma & CXCL13.read more
Citations
More filters
Journal ArticleDOI
Primary Vitreoretinal Lymphoma in HIV Infection
TL;DR: Ophthalmologists should consider the diagnosis of PVRL in HIV-positive individuals who present with intermediate or posterior uveitis, and the prognosis is poor, but has improved significantly compared to the pre-ART era.
Journal ArticleDOI
Changes in cerebrospinal fluid interleukin-10 levels display better performance in predicting disease relapse than conventional magnetic resonance imaging in primary central nervous system lymphoma.
Yan Zhang,Dongmei Zou,Jingjing Yin,Li Zhang,Xiao Zhang,Wei Wang,Meifen Zhang,Daobin Zhou,Wei Zhang +8 more
TL;DR: In this paper, the authors evaluated the value of dynamic interleukin (IL)-10 cerebrospinal fluid (CSF) concentrations for prognosis and relapse prediction in PCNSL.
Journal ArticleDOI
Beyond LNB: Real life data on occurrence and extent of CSF CXCL13 in neuroinflammatory diseases.
Georg Pilz,Regina Steger,Peter Wipfler,Ferdinand Otto,Shahrzad Afazel,Elisabeth Haschke-Becher,Eugen Trinka,Andrea Harrer +7 more
TL;DR: Evidence is provided that CXCL13 elevation occurs at variable extent in the majority of neuroinflammatory diseases, which is not exclusive for LNB.
Journal ArticleDOI
Cerebrospinal fluid interleukin (IL)-10 and IL-10:IL-6 ratio as biomarkers for small B-cell lymphoproliferations with leptomeningeal dissemination.
M Costopoulos,Rathana Kim,Sylvain Choquet,Karim Maloum,Caroline Houillier,Caroline Algrin,Catherine Settegrana,Juliette Villemonteix,Martine Brissard,Claire Quiney,Sophie Bernard,Frederic Davi,Catherine Thieblemont,Khê Hoang-Xuan,Véronique Leblond,Hélène Merle-Béral,Magali Le Garff-Tavernier +16 more
TL;DR: It is reported for the first time that low levels of interleukin (IL)-10 do not exclude lymphomatous meningitis in B-cell lymphoproliferative disorders (CLPD), and the usefulness of adding the IL-10:IL-6 ratio in order to potentially reveal more aggressive lymphomas.
Journal ArticleDOI
Circulating Tumor DNA Profiling for Detection, Risk Stratification, and Classification of Brain Lymphomas
TL;DR: In this article , the authors explored the value of circulating tumor DNA (ctDNA) for early outcome prediction, measurable residual disease monitoring, and surgery-free CNSL identification by applying ultrasensitive targeted next-generation sequencing to a total of 306 tumor, plasma, and CSF specimens from 136 patients with brain cancers, including 92 patients with CNSL.
References
More filters
Journal ArticleDOI
Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine.
Mark H. Zweig,Gregory Campbell +1 more
TL;DR: Receiver-operating characteristic (ROC) plots provide a pure index of accuracy by demonstrating the limits of a test's ability to discriminate between alternative states of health over the complete spectrum of operating conditions.
Journal ArticleDOI
Basic principles of ROC analysis
TL;DR: ROC analysis is shown to be related in a direct and natural way to cost/benefit analysis of diagnostic decision making and the concepts of "average diagnostic cost" and "average net benefit" are developed and used to identify the optimal compromise among various kinds of diagnostic error.
Journal ArticleDOI
Revised response criteria for malignant lymphoma
Bruce D. Cheson,Beate Pfistner,Malik E. Juweid,Randy D. Gascoyne,Lena Specht,Sandra J. Horning,Bertrand Coiffier,Richard I. Fisher,Anton Hagenbeek,Emanuele Zucca,Steven T. Rosen,Sigrid Stroobants,T. Andrew Lister,Richard T. Hoppe,Martin Dreyling,Kensei Tobinai,Julie M. Vose,Joseph M. Connors,Massimo Federico,Volker Diehl +19 more
TL;DR: New guidelines incorporating PET, IHC, and flow cytometry for definitions of response in non-Hodgkin's and Hodgkin's lymphoma are presented and it is hoped that they will be adopted widely by study groups, pharmaceutical and biotechnology companies, and regulatory agencies to facilitate the development of new and more effective therapies to improve the outcome of patients with lymphoma.
Journal ArticleDOI
A Polycistronic MicroRNA Cluster, miR-17-92, Is Overexpressed in Human Lung Cancers and Enhances Cell Proliferation
Yoji Hayashita,Hirotaka Osada,Yoshio Tatematsu,Hideki Yamada,Kiyoshi Yanagisawa,Shuta Tomida,Yasushi Yatabe,Katsunobu Kawahara,Yoshitaka Sekido,Takashi Takahashi +9 more
TL;DR: Findings clearly suggest that marked overexpression of the miR-17-92 cluster with occasional gene amplification may play a role in the development of lung cancers, especially in their most aggressive form, small-cell lung cancer, and that the C13orf25 gene may well be serving as a vehicle in this regard.
Journal ArticleDOI
Report of an International Workshop to Standardize Baseline Evaluation and Response Criteria for Primary CNS Lymphoma
Lauren E. Abrey,Tracy T. Batchelor,A. J. M. Ferreri,Mary Gospodarowicz,Elisa Jacobsen Pulczynski,Emanuele Zucca,Justine R. Smith,Agnieszka Korfel,Carole Soussain,Lisa M. DeAngelis,Edward A. Neuwelt,Brian P. O'Neill,Eckhard Thiel,Tamara Shenkier,Fransesc Graus,Martin J. van den Bent,John F. Seymour,Philip Poortmans,James O. Armitage,Franco Cavalli +19 more
TL;DR: An international group of experts meeting to review current standards of reporting and to formulate a consensus opinion regarding minimum baseline evaluation and common standards for assessing response to therapy hope that these guidelines will improve communication among investigators and comparability among clinical trials in a way that will allow to develop better therapies for patients.
Related Papers (5)
High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial.
Andrés J.M. Ferreri,Michele Reni,Marco Foppoli,Maurizio Martelli,Gerasimus A. Pangalis,Maurizio Frezzato,Maria Giuseppina Cabras,Alberto Fabbri,Gaetano Corazzelli,Fiorella Ilariucci,Giuseppe Rossi,Riccardo Soffietti,Caterina Stelitano,Daniele Vallisa,Francesco Zaja,Lucia Zoppegno,Gian Marco Aondio,Giuseppe Avvisati,Monica Balzarotti,Alba A. Brandes,José Luis Crespo Fajardo,Henry L. Gomez,Attilio Guarini,Graziella Pinotti,Luigi Rigacci,Catrina Uhlmann,Piero Picozzi,Paolo Vezzulli,Maurilio Ponzoni,Emanuele Zucca,Federico Caligaris-Cappio,Franco Cavalli +31 more
Report of an International Workshop to Standardize Baseline Evaluation and Response Criteria for Primary CNS Lymphoma
Lauren E. Abrey,Tracy T. Batchelor,A. J. M. Ferreri,Mary Gospodarowicz,Elisa Jacobsen Pulczynski,Emanuele Zucca,Justine R. Smith,Agnieszka Korfel,Carole Soussain,Lisa M. DeAngelis,Edward A. Neuwelt,Brian P. O'Neill,Eckhard Thiel,Tamara Shenkier,Fransesc Graus,Martin J. van den Bent,John F. Seymour,Philip Poortmans,James O. Armitage,Franco Cavalli +19 more